Fk 506 and Autoimmune Disease: Perspective and Prospects

References

• Kino T., Hatanaka H., Hashimoto M., Nishiyama M., Goto T., Okuhara M., Kohsaka M., Aoki H., Imanaka H. FK 506, a novel immunosuppressant isolated from Streptomyces. I. Fermentation, isolation and physicochemical and biological characteristics. J Antibiot 1987; 40: 1249–1255
   PubMed Web of Science ®Google Scholar
• Kino T., Hatanaka H., Miyata S., Inamura N., Nishiyama M., Yajima T., Goto T., Okuhara M., Kohsaka M., Aoki H., Ochiai T. FK 506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK 506 in vitro. J Antibiot, 40: 1256–1265
   PubMedGoogle Scholar
• Thomson A. W. FK 506. How much potential. Immunol Today 1989; 10: 6–9
   PubMedGoogle Scholar
• Starzl T. E., Fung J., Venkataramanan R., Todo S., Demetris A. J., Jain A. FK 506 for liver, kidney and pancreas transplantation. Lancet 1989; ii: 1000–1004
   Google Scholar
• Kahan B. D., Chang J. Y., Seghal S. N. Preclinical evaluation of a new potent immunosuppressive agent rapamycin. Transplantation 1991; 52: 185–191
   PubMed Web of Science ®Google Scholar
• Fung J. J., Alessiani M., Abu-Elmagd K., Todo S., Shapiro R., Tzakis A., Van Thiel D., Armitage J., Jain A., McCauley J., Selby R., Starzl T. E. Adverse effects associated with the use of FK 506. Transplant Proc 1991; 23: 3105–3108
   PubMed Web of Science ®Google Scholar
• Todo S., Fung J. J., Demetris A. J., Jain A., Venkataramanan R., Starzl T. E. Early trials with FK 506 as primary treatment in liver transplantation. Transplantation Proc 1990; 22: 13–16
   PubMed Web of Science ®Google Scholar
• Shapiro R., Jordan M., Fung J., McCauley J., Johnston J., Iwaki Y., Tzakis A., Hakala T., Todo S., Starzl T. E. Kidney transplantation under FK 506 immunosuppression. Transplant Proc 1991; 23: 920–923
   PubMed Web of Science ®Google Scholar
• Armitage J. M., Kormos R. L., Fung J., Lavee J., Fricker F. J., Griffith B. P. Preliminary experience with FK 506 in thoracic transplantation. Transplantation 1991; 52: 164–167
   PubMed Web of Science ®Google Scholar
• Starzl T. E., Thomson A. W., Todo S., Fung J. J. Proceedings of the first international congress on FK 506. Transplant Proc 1991; 23: 2709–3380
   PubMedGoogle Scholar
• Starzl T. E., Makowka L., Todo S. FK 506: a potential breakthrough in immunosuppression. Transplant Proc 1987; 19: 3–103
   Web of Science ®Google Scholar
• Starzl T. E., Todo S., Fung J. J., Groth C. FK 506. A potential breakthrough in immunosuppression-clinical implications. Transplant Proc 1990; 22: 5–113
   PubMedGoogle Scholar
• Thomson A. W. FK 506: Profile of an important new immunosuppressant. Transplant Rev 1990; 4: 1–13
   Google Scholar
• Macleod A. M., Thomson A. W. FK 506: an immunosuppressant for the 1990′s. Lancet 1991; 337: 25–27
   PubMed Web of Science ®Google Scholar
• Goto T., Kino T., Hatanaka H., Nishiyama M., Okuhara M., Kohsaka M., Aoki H., Imamaka H. Discovery of FK 506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987; 19(Suppl 6)4–8
   PubMed Web of Science ®Google Scholar
• Harding M. W., Galat A., Uehling D. E., Schreiber S. L. A receptor for the immunosuppressant FK 506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989; 341: 758–760
   PubMed Web of Science ®Google Scholar
• Siekierka J. J., Hung S. H. Y., Poe M., Lin S. C., Sigal N. H. A cytosolic binding protein for the immunosuppressant FK 506 has peptid-yl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989; 341: 755–757
   PubMed Web of Science ®Google Scholar
• Tocci M. J., Matkovich D. A., Collier K. A., Kwok P., Dumont F., Lin S., Degudicibus S., Siekierka J. J., Chin J., Hutchinson N. I. The immunosuppressant FK 506 selectively inhibits expression of early T cell activation genes. J Immunol 1989; 143: 718–726
   PubMed Web of Science ®Google Scholar
• Zeevi A., Duquesnoy R., Eiras G., Rabinowich H., Todo S., Makowka L., Starzl T. E. Immunosuppressive effect of FK 506 on in vitro lymphocyte alloactivation: synergism with cyclosporin A. Transplant Proc 1987; 19(Suppl. 6)40–44
   PubMedGoogle Scholar
• Sawada S., Suzuki G., Kawase Y., Takaku F. Novel immunosuppressive agent, FK 506. In vitro effects on the cloned T cell activation. J Immunol 1987; 139: 1797–1803
   PubMed Web of Science ®Google Scholar
• Woo J., Propper D. J., Thomson A. W. Antigen presentation and HLA-DR expression by FK 506-treated human monocytes. Immunology 1990; 71: 551–555
   PubMedGoogle Scholar
• DePaulis A., Cirillo R., Ciccarelli A., Condorelli M., Marone G. FK 506, a potent novel inhibitor of the release of proinflammatory mediators from human FcRI+ cells. J Immunol 1991; 146: 2374–2381
   PubMed Web of Science ®Google Scholar
• Wang S. C., Zeevi A., Tweardy D. J., Jordan M. L., Simmons R. L. FK 506, rapamycin and cyclosporine A: effects on IL-4 and IL-10 mRNA levels in a T helper cell line. Transplant Proc 1991; 23: 2920–2922
   PubMedGoogle Scholar
• Schreiber S. L. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991; 251: 283–287
   PubMed Web of Science ®Google Scholar
• Liu J., Farmer J. D., Lane W. S., Friedman J., Weissman I., Schreiber S. L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK 506 complexes. Cell 1991; 66: 807–815
   PubMed Web of Science ®Google Scholar
• Flanagan W. M., Corthesy B., Bram R. J., Crabtree G. R. Nuclear association of a T-cell transcription factor blocked by FK 506 and cyclosporin A. Nature 1991; 352: 803–807
   PubMed Web of Science ®Google Scholar
• Tamura K., Kobayashi M., Hashimoto K., Kojima K., Nagase K., Iwasaki K., Kaizu T., Tanaka H., Niwa M. A highly sensitive method to assay FK 506 in plasma. Transplant Proc 1987; 19(Suppl 6)23–29
   PubMedGoogle Scholar
• Cadoff E. M., Venkataramanan R., Krajack A., Jain A. S., Fung J. J., Todo S., Starzl T. E. Assay of FK 506 in plasma. Transplant Proc 1990; 22: 50–51
   PubMedGoogle Scholar
• Venkataramanan R., Jain A., Cadoff E., Warty V., Iwasaki K., Nagase K., Krajack A., Imventarza O., Todo S., Fung J. J., Starzl T. E. Pharmacokinetics of FK 506: Preclinical and clinical studies. Transplant Proc 1990; 22: 52–56
   PubMed Web of Science ®Google Scholar
• Venkataramanan R., Jain A., Warty V., Abu-Elmagd K., Furukawa H., Imventarza O., Fung J. J., Todo S., Starzl T. E. Pharmacokinetics of FK 506 following oral administration. A comparison of FK 506 and cyclosporine. Transplant Proc 1991; 23: 931–933
   PubMed Web of Science ®Google Scholar
• O'Hara K., Billington R., James R. W., Dean G. A., Nishiyama M., Noguchi H. Toxicologic evaluation of FK 506. Transplant Proc 1990; 22: 83–86
   PubMedGoogle Scholar
• Reyes J., Tzakis A., Green M., Nour B., Nalesnik M., Van Thiel D., Martin M., Breinig M. K., Fung J. J., Cooper M., Starzl T. E. Post-transplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. Transplant Proc 1991; 23: 3044–3046
   PubMedGoogle Scholar
• Sigal N. H., Dumont F., Durette P., Siekierka J. J., Peterson L., Rich D. H., Dunlap B. E., Slaruch M. J., Melino M. R., Koprak S. L., Williams D., Witzel B., Pisano J. M. Is cyclophilin involved in the nephrotoxic mechanism of action of cyclosporin A. J exp Med 1991; 173: 619–628
   PubMed Web of Science ®Google Scholar
• Woo J., Ross C. S., Milton J. I., Thomson A. W. Immunosuppressive activity of FK 506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal. Clin Exp Immunol 1990; 79: 115–122
   PubMedGoogle Scholar
• Pugh-Humphreys R. G. P., Ross C. S. K., Thomson A. W. The influence of FK 506 on the thymus: an immunophenotypic and structural analysis. Immunoloy 1990; 70: 398–404
   PubMed Web of Science ®Google Scholar
• Woo J., Ildstad S. T., Hronakes M. L., Thomson A. W. Kinetics of early T cell repopulation in the mouse following syngeneic bone marrow transplantation: FK 506 causes a maturational defect of CD4* CD8 T cells. Transplant Proc 1991; 23: 2323–2924
   PubMedGoogle Scholar
• Kawashima H., Mochizuki M. Effects of a new immunosuppressive agent FK 506, on the efferent limb of the immune responses. Exp Eye Res 1990; 51: 565–572
   PubMed Web of Science ®Google Scholar
• Kawashima H., Fujino Y., Mochizuki M. Effects of a new immunosuppressive agent, FK 506, on experimental autoimmune uveoretinitis in rats. Invest Ophthalmol Vis Sci 1988; 29: 1265–1271
   PubMed Web of Science ®Google Scholar
• Mochizuki M., Kawashima H. Effects of FK 506, 15-deoxy-spergualin and cyclosporine on experimental autoimmune uveoretinitis in the rat. Autoimmunity 1990; 8: 37–41
   PubMed Web of Science ®Google Scholar
• Kawashima H., Fujino Y., Mochizuki M. Antigen-specific suppressor cells induced by FK 506 in experimental autoimmune uveoretinitis in the rat. Invest Ophthalmol Vis Sci 1990; 31: 31–38
   Google Scholar
• Ni M., Chan C. -C., Nussenblatt R. B., Mochizuki M. FR900506 (FK 506) and 15-deoxyspergualine (15-DSG) modulate the kinetics of infiltrating cells in eyes with experimental autoimmune uveoretinitis. Autoimmunity 1990; 8: 43–51
   PubMed Web of Science ®Google Scholar
• Liversidge J., Thomson A. W., Forrester J. V. FK 506 modulates accessory cell adhesion molecule expression and inhibits CD4′ lymphocyte adhesion to retinal pigment epithelial cells in vitro; implications for therapy of uveoretinitis. Transplant Proc 1991; 23: 3339–3342
   PubMedGoogle Scholar
• Fujino Y., Mochizuki M., Raber J., Kotake S., Gery I., Nussenblatt R. B. FK 506 treatment of S-antigen induced uveitis in primates. Invest Ophthalmol Vis Sci 1990; 31: 61
   Google Scholar
• Inamura N., Hashimoto M., Nakahara K., Aoki H., Yamaguchi 1., Kohsaka M. Immunosuppressive effect of FK 506 on collagen-induced arthritis in rats. Clin Immunol Immunopathol 1988; 46: 82–90
   PubMedGoogle Scholar
• Arita C., Hotokebuchi T., Miyahara H., Arai K., Sugioka Y., Takagishi K., Kaibara N. Inhibition by FK 506 of established lesions of collagen-induced arthritis in rats. Clin Exp Immunol 1990; 82: 456–461
   PubMedGoogle Scholar
• Takagishi K., Yamamoto M., Nishimura A., Yamasaki G., Kanazawa N., Hotokebuchi T., Kaibara N. Effects of FK 506 on collagen arthritis in mice. Transplant Proc 1989; 21: 1053–1055
   PubMedGoogle Scholar
• Murase N., Lieberman I., Nalesnik M., Mintz D., Todo S., Drash A. L., Starzl T. E. FK 506 prevents spontaneous diabetes in the BB rat. Lancet 1990; ii: 373–374
   Google Scholar
• Miyagawa J., Yamamoto K., Hanafusa T., Itoh N., Nakagawa C., Otsuka A., Katsura H., Yamagata K., Miyazaki A., Kono N., Tarui S. Preventive effect of a new immunosuppressant FK 506 on insulinitis and diabetes in non-obese diabetic mice. Diahct-ologia 1990; 33: 503–505
   Google Scholar
• Takabayashi K., Koike T., Kurasawa K., Matsumura R., Sato T., Tomioka H., Ilo I., Yoshiki T., Yoshida S. Effects of FK 506, a novel immunosuppressive drug on murine systemic lupus erythematosus. Clin Immunol Immunopathol 1989; 51: 110–117
   PubMedGoogle Scholar
• Yamamoto K., Mori A., Nakahama T., Ilo M., Okudaira H., Miyamoto T. Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK 506. Immunology 1988; 69: 222–227
   Google Scholar
• Okuba Y., Tsukada Y., Maezawa A., Ono K., Yano S., Naruse T. FK 506, a novel immunosuppressive agent, induces antigen-specific immunotolerance in active Heymann's nephritis and in the autologous phase of Masugi nephritis. Clin Exp Immunol 1990; 82: 450–455
   PubMedGoogle Scholar
• Hara S., Fukatsu A., Suzuki N., Sakamoto N., Matsuo S. The effects of a new immunosuppressive agent, FK 506, on the glomerular injury in rats with accelerated nephrotoxic serum glomerulonephritis. Clin Immunol Immunopathol 1990; 57: 351–362
   PubMedGoogle Scholar
• Inamura N., Hashimoto M., Nakahara K., Nakajima Y., Nishio M., Aoki H., Yamaguchi I., Kohsaka M. Immunosuppressive effect of FK 506 on experimental allergic encephalomyelitis in rats. Im J Immunopharmacol 1988; 10: 991–995
   PubMedGoogle Scholar
• Bolton C. The ability of myelin basic protein-sensitized leukocytes to adoptively transfer experimental allergic encephalomyelitis following coculture with FK 506, cyclosporine, or prednisone. Transplant Proc 1991; 23: 3363–3364
   PubMedGoogle Scholar
• Jegasothy B., Ackerman C. D., Todo S., Fung J., Starzl T. E. FK 506-a new therapeutic agent for severe, recalcitrant psoriasis. Arch Dermatol
   Google Scholar
• Abu-Elmagd K., Van Thiel D. H., Jegasothy B. V., Ackerman C. D., Todo S., Fung J. J., Thomson A. W., Starzl T. E. FK 506-a new therapeutic agent for severe, recalcitrant psoriasis. Transplant Proc 1991; 23: 3322–3324
   PubMed Web of Science ®Google Scholar
• Thomson A. W., Nalesnik M., Abu-Elmagd K., Starzl T. E. Influence of FK 506 on T lymphocytes, Langerhans cells, and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: a preliminary study. Transplant Proc 1991; 23: 3330–3331
   PubMedGoogle Scholar
• Abu-Elmagd K., Jegasothy B. V., Ackerman C. D., Thomson A. W., Rilo H., Nikolaidis N., Van Thiel D., Fung J. J., Todo S., Starzl T. E. Efficacy of FK 506 in the treatment of pyoderma gangrenosum. Transplant Proc 1991; 23: 3328–3329
   PubMedGoogle Scholar
• Mochizuki M., Masuda K., Sakane T., Inaba G., Ito K., Kogure M., Sugino N., Usui M., Mizushima Y., Ohno S., Miyanaga Y., Hayasaka S., Ohizumi K. A multicentre clinical open trial of FK 506 in refractory uveitis, including Behcet's disease. Transplant Proc 1991; 23: 3343–3346
   PubMed Web of Science ®Google Scholar
• McCauley J., Tzakis A. G., Fung J. J., Todo S., Starzl T. E. FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet 1990; i: 674
   Google Scholar
• McCauley J., Shapiro R., Scantlebury V., Gilboa N., Jordan M., Jensen C., Naik A., Tzakis A., Ellis D., Starzl T. E. FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. Transplant Proc 1991; 23: 3354–3356
   PubMedGoogle Scholar
• Armitage J. M., Fricker F. J., Del Nido P., Cipriani L., Starzl T. E. The clinical trial of FK 506 as primary and rescue immunosuppression in pediatric cardiac transplantation. Transplant Proc 1991; 23: 3058–3060
   PubMed Web of Science ®Google Scholar